Novadip Biosciences SA Announces First Pediatric Patient with Congenital Pseudoarthrosis of the Tibia Undergoes Implantation with NVD-003, an Autologous Tissue Regeneration Product, in Phase 1b/2a US/EU Clinical Trial
Second patient scheduled for implantation with NVD-003 in June 2023 Pivotal trial is expected to begin in the second half of 2024* Novadip Biosciences SA ("Novadip" or "the Company"), a clinical-stage
Bruxelles Capitale J Pediatr Orthop Pierre Louis Docquier Denis Dufrane Novadip Biosciences Acta Orthop Scand
Source: finanznachrichten.de